Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
Adelaide Medical School, University of Adelaide, Adelaide, Australia.
Biochem J. 2019 Nov 15;476(21):3211-3226. doi: 10.1042/BCJ20190245.
Sphingosine kinase 1 (SK1) is a signalling enzyme that catalyses the phosphorylation of sphingosine to generate the bioactive lipid sphingosine 1-phosphate (S1P). A number of SK1 inhibitors and chemotherapeutics can induce the degradation of SK1, with the loss of this pro-survival enzyme shown to significantly contribute to the anti-cancer properties of these agents. Here we define the mechanistic basis for this degradation of SK1 in response to SK1 inhibitors, chemotherapeutics, and in natural protein turnover. Using an inducible SK1 expression system that enables the degradation of pre-formed SK1 to be assessed independent of transcriptional or translational effects, we found that SK1 was degraded primarily by the proteasome since several proteasome inhibitors blocked SK1 degradation, while lysosome, cathepsin B or pan caspase inhibitors had no effect. Importantly, we demonstrate that this proteasomal degradation of SK1 was enabled by its ubiquitination at Lys183 that appears facilitated by SK1 inhibitor-induced conformational changes in the structure of SK1 around this residue. Furthermore, using yeast two-hybrid screening, we identified Kelch-like protein 5 (KLHL5) as an important protein adaptor linking SK1 to the cullin 3 (Cul3) ubiquitin ligase complex. Notably, knockdown of KLHL5 or Cul3, use of a cullin inhibitor or a dominant-negative Cul3 all attenuated SK1 degradation. Collectively this data demonstrates the KLHL5/Cul3-based E3 ubiquitin ligase complex is important for regulation of SK1 protein stability via Lys183 ubiquitination, in response to SK1 inhibitors, chemotherapy and for normal SK1 protein turnover.
丝氨酸棕榈酰转移酶激酶 1(SK1)是一种信号酶,能够催化鞘氨醇磷酸化为具有生物活性的鞘氨醇 1-磷酸(S1P)。许多 SK1 抑制剂和化疗药物可以诱导 SK1 的降解,这种促生存酶的丧失被证明对这些药物的抗癌特性有显著贡献。在这里,我们定义了 SK1 抑制剂、化疗药物和自然蛋白周转对 SK1 降解的机制基础。使用可诱导的 SK1 表达系统,使我们能够独立于转录或翻译效应评估预先形成的 SK1 的降解,我们发现 SK1 主要通过蛋白酶体降解,因为几种蛋白酶体抑制剂阻止了 SK1 的降解,而溶酶体、组织蛋白酶 B 或泛半胱天冬酶抑制剂没有影响。重要的是,我们证明了 SK1 的这种蛋白酶体降解是通过其在赖氨酸 183 处的泛素化来实现的,这似乎是由 SK1 抑制剂诱导的 SK1 结构中该残基周围的构象变化所促进的。此外,我们使用酵母双杂交筛选鉴定 Kelch 样蛋白 5(KLHL5)作为一种重要的蛋白质衔接物,将 SK1 与 cullin 3(Cul3)泛素连接酶复合物连接起来。值得注意的是,KLHL5 或 Cul3 的敲低、使用 cullin 抑制剂或显性负 Cul3 都减弱了 SK1 的降解。总的来说,这些数据表明 KLHL5/Cul3 基 E3 泛素连接酶复合物通过赖氨酸 183 泛素化对 SK1 蛋白稳定性的调节很重要,这是对 SK1 抑制剂、化疗和正常 SK1 蛋白周转的反应。